Real-world evidence and patient preference for subcutaneous < em > versus < /em > intravenous natalizumab in the treatment of relapsing-remitting multiple sclerosis - initial results from the observational SISTER study

CONCLUSION: Based on current data, there is a trend toward patients' preference for the natalizumab SC route over the IV route, which provides valuable insights into patients' preference for natalizumab RoA in routine care and complements available data from clinical studies with real-world data on SC natalizumab.TRIAL REGISTRATION: This observational (non-interventional) study was registered in the local German PEI register for non-interventional studies (NIS-No. 611) and in the international CTgov register (NCT05304520).PMID:38616781 | PMC:PMC11015759 | DOI:10.1177/17562864241241382
Source: Adv Data - Category: Epidemiology Authors: Source Type: research